Kratom Identity Testing Explained: DNA Barcoding, Microscopy and Chemical Fingerprints

The short answer

Kratom identity testing asks a deceptively simple question:
Is this material actually what the label and purchase order say
it is? A useful answer usually requires more than one piece of
evidence.

Visual examination can reveal whether intact leaves have the expected
form and whether obvious foreign material is present. Microscopy can
examine diagnostic plant structures that remain after grinding. DNA
methods can compare recoverable genetic regions with authenticated
references. Chromatographic or spectrometric methods can compare a
chemical pattern with authenticated Mitragyna speciosa material
and quantify selected alkaloids. Supplier records, lot traceability and
representative sampling connect those results to the material that was
actually packaged and sold.

These tools overlap, but they are not interchangeable. DNA can
support species identity without proving alkaloid strength. A
mitragynine result can support chemical consistency without proving that
every plant particle is Mitragyna speciosa. A photograph can
show green powder without establishing its species. A laboratory name
and a “pass” badge do not explain the method, reference, acceptance
criteria or sample chain of custody.

The strongest identity case is therefore a fit-for-purpose
evidence package, not a single impressive-sounding test.

Identity
is different from potency, purity and safety

Quality documents often place several distinct questions on one page.
Keeping those questions separate prevents a common reading mistake:
treating one passing result as proof of everything.

Question	What it asks	Examples of relevant evidence	What it does not automatically prove
Identity	Is the material the claimed ingredient and plant part?	Macroscopy, microscopy, DNA comparison, chemical fingerprint, authenticated reference	Potency, absence of pathogens, legal status
Strength or composition	How much of a stated constituent is present?	Validated quantitative assay, units, sample basis, reference standards	Botanical species by itself
Purity	Is the material diluted, substituted or mixed with unintended matter?	Microscopy, targeted and untargeted chemistry, mass balance, supplier controls	Complete absence of every possible adulterant
Contaminants	Are specified hazards below established limits?	Microbiology, heavy metals, pesticide, solvent, mycotoxin and foreign-material testing	Identity unless the test was designed for identity
Legal category	Which rules apply to this product in a destination jurisdiction?	Current statutes, regulations and agency actions	Product identity or safety

FDA’s dietary-supplement current good manufacturing practice
regulation defines quality in terms of established specifications for
identity, purity, strength, composition and contaminant limits. It
separately requires an identity specification for each dietary
ingredient component and at least one appropriate identity test or
examination before use, unless FDA grants a petitioned exemption. Kiody
uses these requirements as quality-literacy benchmarks; mentioning them
does not mean FDA approves kratom or considers it lawfully marketed.

FDA’s current position is that kratom is not lawfully marketed in the
United States as a dietary supplement, conventional-food additive,
prescription drug or over-the-counter drug. Identity testing cannot
change that federal position, confer FDA approval or override a state or
local restriction.

Start by
defining exactly what must be identified

“Kratom” is not a complete laboratory specification. Before choosing
a method, define the claimed material precisely enough that a result can
be evaluated.

A useful identity description may include:

• Scientific name: Mitragyna speciosa (Korth.) Havil.
• Common name: kratom.
• Plant part: leaf, rather than an unspecified aerial part, stem or
  mixed material.
• Physical form: whole leaf, cut leaf, powder, extract, liquid or
  finished capsule.
• Processing state: dried, milled, heat-treated, extracted, blended or
  otherwise processed.
• Added ingredients: capsule shell, flavor, carrier, sweetener or
  other declared component.
• Product category: unenhanced botanical material, extract, enhanced
  product or concentrated 7-OH product.
• Reference material: the authenticated specimen or chemical reference
  to which the sample is compared.
• Acceptance criteria: the observable or measured features required
  for a pass.

This matters because “green powder,” “red vein,” “premium,” “10x” and
“lab tested” are not scientific identities. A color name may be a
commercial or processing description. It does not replace the species,
plant part and formulation statement.

The material’s form also controls which methods are realistic. Intact
leaf retains structural features that may be lost in a fine powder.
Powder may retain microscopic plant structures but not the macroscopic
shape of a leaf. Extraction can remove DNA, cellular structures and
poorly soluble compounds while enriching others. A flavored liquid can
contain botanical-derived chemistry but provide little useful
microscopy. A tablet may combine multiple components that complicate
both DNA recovery and chemical interpretation.

An identity-testing map

No method is “best” in the abstract. The practical question is which
combination is suitable for the sample and the claim.

Method	Most useful for	Typical strength	Major limitation
Macroscopic examination	Whole or cut leaves	Fast review of gross morphology and visible foreign material	Weak for finely ground or extracted material
Microscopy	Leaf fragments and powder	Examines plant structures that can survive milling	Requires botanical expertise and authenticated comparison
DNA barcoding or targeted DNA	Raw leaf and some powders	Supports taxonomic identity through genetic comparison	Processing may damage DNA; species identity does not prove composition or strength
HPTLC/HPLC/UPLC fingerprint	Powder, extract and many finished forms	Compares a pattern of multiple chemical features	Similarity rules and references must be predefined
Targeted alkaloid assay	Powder, extracts and finished products	Quantifies named analytes such as mitragynine and 7-OH	One marker is not a complete species or adulteration test
LC-MS/QTOF or GC-MS profiling	Complex investigations and broad comparisons	Adds higher-information chemical characterization	More data do not guarantee correct identification without suitable libraries and references
Infrared or near-infrared spectroscopy	High-throughput incoming-material screening	Rapid comparison after a robust model is built	Model can fail outside its training range or with changed moisture, particle size or matrix

An identity program can use a rapid screening method for routine lots
and reserve a more specific confirmatory method for failures, new
suppliers, unusual matrices or periodic verification. That is different
from using a vague screen as the only evidence for every product.

1.
Macroscopic examination: what the eye can establish

Macroscopy evaluates visible characteristics such as leaf shape,
venation, margins, surface, color, texture and the presence of stems,
insects, stones, plastic or other foreign matter. FDA’s Macroanalytical
Procedures Manual includes a general method for spices, herbs,
botanicals and crude drugs marketed as dried plant parts in different
forms. The manual describes sample examination, separation and reporting
approaches for macroscopic defects and foreign matter.

For intact or coarsely cut leaf, this can be an efficient first
layer. A qualified analyst may compare the sample with an authenticated
voucher or botanical reference and document diagnostic features.
Photographs can create an audit trail if scale, lighting, sample
identification and observed features are recorded.

Macroscopy becomes less discriminating as particle size decreases.
Once leaf is milled into a uniform powder, gross leaf architecture is
destroyed. Color alone is particularly weak. Lighting, camera
processing, drying, storage, oxidation, particle size and blending can
all influence appearance. Two genuine lots may look different, while an
unrelated green powder may look similar.

A visual check is useful, but “looks like kratom” should not be the
whole identity specification for fine powder or extracts.

2.
Microscopy: looking for diagnostic plant structures

Microscopy examines cellular and tissue features rather than overall
leaf shape. Depending on the plant and preparation, an analyst may
evaluate epidermal cells, stomata, trichomes, fibers, vessels, crystals
and other structures. A powder can retain fragments of these features
after the whole leaf’s shape is gone.

The method is strongest when:

• The laboratory has an authenticated M. speciosa
  reference.
• The analyst knows which features are diagnostic and which merely
  occur in many plants.
• The sample preparation and magnification are documented.
• Acceptance criteria describe the required and exclusionary
  features.
• Analysts are trained and periodically checked for consistent
  interpretation.
• The report identifies the plant part and matrix evaluated.

Microscopy can also reveal unexpected starch granules, fibers or
tissue types that suggest substitution, dilution or cross-contact. But
it is not a universal detector. Fine milling may damage features.
Extracts and clarified liquids may contain no diagnostic tissue. A mixed
formula may produce overlapping structures. Heat or other processing can
alter the sample.

“Microscopy passed” is therefore incomplete without the method,
reference, observations and conclusion. A photograph of one field of
view is not necessarily representative of the lot.

3.
DNA methods: powerful taxonomic evidence with important limits

DNA barcoding compares selected genetic regions from a sample with
authenticated reference sequences. Other DNA approaches may use targeted
primers, high-resolution melting profiles, sequencing or combinations of
regions. Research has shown that DNA-based methods can distinguish
M. speciosa from allied Mitragyna species under
studied conditions.

A 2021 Scientific Reports study evaluated DNA barcoding
coupled with high-resolution melting and reported that ITS2 melting
profiles could differentiate M. speciosa from allied species in
the tested sample set. A 2026 study in Plants combined nine DNA
regions with UHPLC, GC-MS and LC-MS/QTOF chemical characterization,
illustrating why genetic and chemical evidence can complement each other
rather than compete.

DNA evidence can answer, “Does recoverable genetic material in this
sample match the claimed taxon under this method?” It does not
automatically answer:

• How much kratom material is present.
• Whether the sample has the declared mitragynine or 7-OH
  concentration.
• Whether a detected species is the only plant present.
• Whether every particle or container in the lot matches the tested
  portion.
• Whether the product is free of pathogens, metals, pesticides,
  solvents or undeclared drugs.
• Whether the product is legal to manufacture, sell, possess or
  ship.

Processing is a central limitation. Heat, extraction, purification,
long storage, acidic conditions and other steps can fragment or remove
DNA. A negative or inconclusive DNA result in an extract may reflect
matrix limitations rather than prove that no kratom-derived material is
present. Conversely, small amounts of plant DNA may be detectable even
when the finished product’s composition is driven by added concentrates
or other ingredients.

Reference quality matters as much as instrument capability. A
database match is only as reliable as the reference sequence, taxonomic
authentication, region choice and comparison rules. A report should
identify the genetic region or assay, reference database or material,
quality controls and result interpretation. “PCR tested” without those
details is not an identity conclusion.

4.
Chemical fingerprints: evaluating a pattern, not just one peak

A chemical fingerprint compares multiple features in a sample with a
defined reference or acceptance region. Depending on the method, the
pattern may include chromatographic retention times, relative peak
areas, mass spectra or selected ratios. HPTLC, HPLC, UPLC, LC-MS and
related techniques can all contribute to fingerprinting.

This approach can remain useful after grinding and, with appropriate
method development, after extraction. It can help assess whether a lot
resembles authenticated kratom material chemically and whether expected
markers are present in a plausible pattern.

But a fingerprint is not self-interpreting. A defensible method
should explain:

• Which peaks or regions are required.
• Which authenticated lots established the reference range.
• Whether the reference represents leaf, extract or the same
  finished-product matrix.
• How retention-time shifts and relative-area variation are
  handled.
• What similarity score or decision rule constitutes a pass.
• How the method treats moisture, particle size, extraction yield and
  concentration.
• Which unexpected features trigger investigation.

Natural products vary. Research on authenticated kratom plants and
commercial materials has reported chemical variation and distinguishable
chemotypes. That means legitimate botanical variation must be considered
when building an acceptance model. It does not mean any chromatogram
with a mitragynine peak should pass.

FDA’s botanical-drug guidance describes chemical characterization and
characteristic profiles as part of a totality-of-evidence approach when
a botanical mixture cannot be fully characterized. That drug guidance
does not make kratom an approved botanical drug and is not a universal
retail standard. It is useful here only as a scientific illustration:
complex botanicals often require more than a single marker.

5.
Targeted alkaloid testing: essential composition data, incomplete
identity proof

Targeted assays quantify selected compounds, commonly mitragynine and
7-OH and sometimes a broader alkaloid panel. A valid quantitative report
should identify the analyte, method, units, sample basis, reporting
limit and relevant reference standards.

Finding mitragynine can support a kratom-related chemical identity,
but one marker is not necessarily unique enough to establish the
complete botanical identity or plant part. Quantitation also cannot show
whether the analyte came from ordinary leaf, an added extract, a
fortified material or a manufactured source unless the method and
surrounding evidence address that question.

This distinction is especially important for 7-OH. Natural botanical
leaf contains 7-OH only as a minor alkaloid, while concentrated or
enhanced products can present a very different composition. A result
should be evaluated in the correct units and against the correct
denominator. Percent by product weight, percent of total alkaloids,
milligrams per serving and parts per million on a dry-weight basis are
not interchangeable.

For example:

• 0.04% w/w equals 400 ppm by weight.
• 2% of total alkaloids cannot be converted into
  product-weight percent without knowing the measured total-alkaloid
  content and compatible bases.
• 1 mg per serving depends on the defined serving size
  and does not by itself state a concentration.

A broad identity program should use alkaloid data alongside
product-form information, supplier records and another suitable identity
technique where needed.

6.
Spectroscopic screening: speed depends on a trustworthy model

Infrared and near-infrared instruments can compare a sample’s
spectral response with a chemometric model. Once a representative model
is validated, these tools may screen incoming powders rapidly and with
little preparation.

The model is the method. Its performance depends on the authenticated
materials used to train and challenge it. A model built from a small set
of one supplier’s dry powders may not be reliable for material from new
origins, different grinders, different moisture levels, heat-treated
lots, extracts or mixtures.

Questions for a spectral identity method include:

• How many authenticated lots and suppliers were in the training
  set?
• Did the validation include closely related species and realistic
  adulterants?
• Were moisture and particle-size variation represented?
• Is the sample matrix within the model’s validated scope?
• What score defines a pass, fail or inconclusive result?
• How are model updates controlled?
• Which confirmatory test follows an atypical result?

A rapid scan can be a strong routine control when these questions are
answered. It is weak when the only documentation is a green check mark
generated by proprietary software.

Why orthogonal evidence
matters

“Orthogonal” methods rely on meaningfully different properties.
Microscopy examines plant structures. DNA examines genetic sequences or
profiles. Chromatography examines chemical behavior. Supplier
documentation and chain of custody establish provenance and
traceability.

Using two methods is not automatically orthogonal. Two assays that
both detect only mitragynine may repeat the same limitation. A valuable
combination addresses different failure modes.

Examples include:

• Whole leaf: macroscopic authentication plus a
  chemical fingerprint.
• Powder: microscopy or DNA plus a chemical
  fingerprint and quantitative alkaloid panel.
• Extract: chemical fingerprint plus targeted
  alkaloid quantitation, supported by authenticated raw-material
  records.
• Pure-leaf capsules: identity work on the received
  leaf powder, capsule fill-weight controls and finished-batch
  verification.
• Multi-ingredient product: ingredient-specific
  incoming tests plus a finished-product method shown to work in the full
  matrix.

The combination should be justified before results are known.
Choosing an additional test only after an inconvenient result can create
confirmation bias.

Sampling comes before
testing

An excellent method can accurately identify a sample that does not
represent the lot. Identity confidence therefore begins before the
material reaches the laboratory.

A sampling plan should define the lot, number of containers,
locations sampled, increments per container, tools, sample mass,
compositing decision, cleanliness controls, seals, custody transfers and
reserve-sample handling. Risks change with the lot’s structure. A single
sealed drum is different from 200 bags filled across multiple shifts. A
stratified powder blend may require different sampling than a
homogeneous liquid.

Composite samples can be efficient, but they can dilute a localized
substitution or mix-up. Individual-container testing provides more
location information but costs more. The plan should explain the
tradeoff and the basis for representativeness.

The laboratory report should be reconciled to:

• Supplier and manufacturer lot numbers.
• Product and material name.
• Sample ID and seal number.
• Sampling date and sampler.
• Laboratory accession number.
• Test dates and report date.
• Packaged-product lot or batch record.

If those identifiers do not connect, the COA may accurately describe
a jar in the laboratory while saying little about the pouch in a
customer’s hand.

A practical identity
specification

A specification should tell a reviewer what is tested and how the
result becomes a decision. A usable template can contain:

1. Material name: Mitragyna speciosa dried
   leaf powder.
2. Plant part: leaf.
3. Processing state: dried, milled and
   unenhanced.
4. Matrix: bulk botanical powder.
5. Primary identity method: named microscopy, DNA or
   fingerprint procedure.
6. Reference: authenticated voucher, sequence
   accession, reference lot or chemical standard.
7. Acceptance criteria: explicit required features,
   match criteria or similarity range.
8. Controls: positive, negative, blank and
   system-suitability controls as applicable.
9. Sample plan: procedure number and required sample
   size.
10. Result categories: pass, fail and
    inconclusive.
11. Retest rule: when retesting is permitted and how a
    new representative sample is obtained.
12. Escalation: confirmatory testing, supplier
    investigation and material hold.

“Conforms” is meaningful only when this underlying specification
exists.

How to read an identity
result on a COA

Use the following 12-step review.

Step 1: Match the product and
lot

Confirm that the report names the same product form and lot printed
on the package. Similar product names are not enough.

Step 2: Identify who
collected the sample

Determine whether the laboratory, manufacturer, supplier or an
unknown party supplied the test portion. This affects what the report
can establish about representativeness.

Step 3: Find the exact matrix

Look for whole leaf, powder, capsule contents, extract, liquid or
finished tablet. A method valid for leaf powder may not be valid for a
flavored liquid.

Step 4: Locate the identity
method

“Botanical identity,” “HPLC” or “DNA” is not a complete method
description. Look for a method number or a clear procedure name.

Step 5: Find the
claimed taxon and plant part

The report should not stop at “kratom.” Look for Mitragyna
speciosa and, when relevant, leaf.

Step 6: Identify the
reference

Determine what authenticated material, database sequence, spectrum or
chromatographic profile was used for comparison.

Step 7: Read the acceptance
criteria

The report or linked specification should explain what constitutes a
pass. A conclusion without a decision rule is hard to audit.

Step 8: Check controls
and suitability

Method-specific controls help show that the run could produce a valid
result. For example, DNA work may need extraction and amplification
controls; chromatography may need blanks, standards and
system-suitability checks.

Step 9:
Separate identity from alkaloid concentration

Do not assume a mitragynine percentage is the identity test unless
the validated procedure and specification establish that use.

Step 10: Review dates
and report status

Check sample receipt, testing, approval and revision dates. Confirm
that the report is final and that later revisions have not replaced
it.

Step 11: Verify laboratory
scope

Laboratory accreditation can support competence, but the certificate
alone is not enough. Confirm the site, method, analyte and matrix are
within the technical scope when the lab claims accredited testing.

Step 12:
Reconcile the decision with batch release

Identity evidence is one part of release. Review contaminants,
composition, packaging, labeling, deviations and lot documentation
separately.

Five fictional identity
reviews

These examples are educational and do not describe actual Kiody or
competitor lots.

Example
1: Whole-leaf sample with two complementary methods

A supplier sends intact dried leaves. A qualified analyst documents
macroscopic features against an authenticated voucher. A chromatographic
fingerprint also falls within the approved similarity range. The sample
identifiers match the sealed lot.

Assessment: Stronger identity evidence because the
two methods evaluate different properties and the sample connection is
documented. Contaminant and composition testing are still separate.

Example
2: Green powder with only a mitragynine result

A COA reports 1.2% mitragynine and labels the row “identity/potency.”
It provides no microscopy, DNA result, fingerprint, reference or
acceptance criteria.

Assessment: The result supports the presence and
measured amount of mitragynine under the stated assay. It does not by
itself establish the full botanical identity, plant part, absence of
added extract or purity of the powder.

Example 3:
Extract with an inconclusive DNA result

A liquid extract produces too little amplifiable DNA. The report
marks species identity inconclusive. A validated extract-specific
chemical fingerprint and quantitative alkaloid profile match approved
reference extract lots, while raw-material records trace the extraction
batch to authenticated leaf.

Assessment: The DNA result should remain
inconclusive, not be relabeled as a pass. The total evidence may still
support an identity decision if the chemical methods and traceability
are scientifically justified for that matrix.

Example 4: DNA
match without lot traceability

A vendor posts a DNA report for “kratom powder,” but the report has
no supplier lot, package lot or collection information. The report is
two years older than the product’s manufacture date.

Assessment: The report may describe the tested
sample accurately, but it is not adequately connected to the current
product lot.

Example
5: Spectral screen outside the validated model

A near-infrared model was validated for dry unenhanced powder. The
same pass/fail model is used on a sweetened liquid extract without
additional validation.

Assessment: The result is outside the documented
scope. A new matrix-specific method or validation is needed.

Twenty warning signs

One warning sign does not prove misconduct, but several should prompt
questions.

1. The report says only “green powder” instead of naming the
   species.
2. The plant part is missing.
3. “Organoleptic” or “visual” is the only identity test for fine
   powder.
4. A mitragynine number is presented as proof of every identity and
   purity claim.
5. DNA is advertised as proof of potency.
6. A negative DNA result in an extract is automatically treated as
   absence of kratom.
7. The reference material or database is not identified.
8. No acceptance criterion is available.
9. The test method is listed only as “in-house” with no procedure
   identifier.
10. A method validated for powder is used for a liquid, gummy or tablet
    without matrix evidence.
11. The laboratory location differs from the accredited location and no
    explanation is provided.
12. The technical accreditation scope does not include the claimed test
    or matrix.
13. The COA lacks a lot number.
14. The package lot and COA lot do not match.
15. The test predates the manufactured lot.
16. The report is a cropped image that hides signatures, revision status
    or sample details.
17. A QR code leads to one generic report for every lot.
18. A retest passes without documenting why the original sample
    failed.
19. “Third-party tested” is used without naming the laboratory or
    providing a report.
20. Identity, safety, legality and FDA approval are treated as the same
    claim.

Questions to ask a
supplier or laboratory

Supplier questions

• What is the exact scientific identity and plant part?
• Is the material unenhanced botanical leaf, an extract or a
  blend?
• How is each incoming lot authenticated?
• Who collects the laboratory sample?
• How is the supplier lot connected to the finished Kiody batch?
• Which changes require requalification of the supplier or
  method?
• How are failed or inconclusive identity results handled?
• Are reserve samples retained?
• Can the full, unredacted final report be authenticated with the
  laboratory?

Laboratory questions

• What method and revision were used?
• Is the method validated or verified for this exact matrix?
• What reference material or sequence supports the conclusion?
• What are the pass, fail and inconclusive criteria?
• Which positive, negative and blank controls were run?
• Can the method distinguish M. speciosa from closely related
  species?
• Can it detect mixtures, or only identify the predominant detectable
  material?
• How do heat, extraction and excipients affect performance?
• Is the test included within the laboratory’s current accreditation
  scope?
• What result would trigger confirmation by a different method?

A 50-field identity review
record

For internal quality review, record enough information that another
qualified person can reconstruct the decision.

1. Review record number
2. Review date
3. Reviewer
4. Material name
5. Scientific name
6. Author citation, if used
7. Common name
8. Plant part
9. Physical form
10. Processing state
11. Botanical, extract or enhanced category
12. Declared added ingredients
13. Supplier name
14. Supplier site
15. Supplier lot
16. Purchase-order number
17. Receipt date
18. Quantity received
19. Number of containers
20. Internal lot number
21. Sampling procedure
22. Sampler
23. Sampling date
24. Containers sampled
25. Increment locations
26. Composite or individual sample
27. Sample mass
28. Sample seal number
29. Chain-of-custody record
30. Laboratory name
31. Laboratory location
32. Accreditation body
33. Certificate status
34. Relevant technical-scope entry
35. Laboratory accession number
36. Matrix named on report
37. Primary identity method
38. Method revision
39. Reference material or database
40. Acceptance criteria
41. Controls reviewed
42. System suitability reviewed
43. Primary result
44. Result classification
45. Confirmatory method
46. Confirmatory result
47. Deviation or investigation number
48. Quality-unit disposition
49. Finished-batch linkage
50. Approval signature and date

Product-form notes

Whole and cut leaf

Macroscopic examination is most informative before milling destroys
gross morphology. Identity evidence should still be linked to a defined
supplier lot and supported by another method when risk warrants it.

Botanical powder

Powder is well suited to microscopy, DNA methods when recoverable
material is present and chemical fingerprinting. The sampling plan
matters because powders can segregate or be mixed unevenly.

Pure-leaf capsules

The capsule format does not make leaf an extract. Kiody’s capsules
contain approximately 500 mg of pure botanical leaf per capsule.
Identity control should connect the received leaf-powder lot to the
encapsulation batch, while capsule fill weight and finished-count
controls address different questions.

Extracts

Extracts may lose morphological features and amplifiable DNA.
Chemical fingerprinting, quantitative composition and authenticated
raw-material traceability become more important. An extraction ratio
such as 10:1 is not an identity result or a measured potency value.

Enhanced leaf

Enhanced leaf combines botanical material with added extract or
alkaloid-rich material. A leaf identity result does not quantify or
identify the enhancement. The specification must cover both the carrier
leaf and the added component.

Concentrated 7-OH products

These products should not be confused with ordinary botanical leaf.
Product-weight percentage, total-alkaloid percentage and milligrams per
serving must be stated separately. Kiody does not sell concentrated
7-OH.

Manufactured derivatives

MGPI, MGM-15 and MGM-16 are not ordinary botanical product
categories. They were temporarily placed in federal Schedule I effective
August 26, 2026. A September 1 Department of Justice
enforcement-discretion statement concerning incidental trace MGPI in
otherwise botanical-consistent material did not remove MGPI from
Schedule I or create a numerical legal exemption. Kiody does not sell
these substances.

Current federal
context as of September 3, 2026

Identity testing is not a shortcut around regulatory status.

FDA states that kratom is not lawfully marketed as a dietary
supplement, conventional-food additive, prescription drug or
over-the-counter drug. FDA also warns about serious adverse events and
has taken action involving contaminated or unlawfully marketed
products.

The federal proceeding concerning 7-OH above a threshold remains
proposed, not final. HHS extended public comments
through September 10, 2026. The proposal should not be described as a
completed federal ban on ordinary botanical leaf.

The separate DEA order temporarily placing MGPI, MGM-15 and MGM-16 in
Schedule I became effective August 26, 2026. That final order should not
be confused with the still-pending 7-OH threshold proceeding.

State and local requirements can be stricter, can use different
thresholds and can regulate botanical leaf, extracts and manufactured
products differently. Check Kiody’s nationwide botanical-leaf and 7-OH
trackers before any commerce decision. A laboratory identity pass does
not authorize shipment.

Responsible-use perspective

Identity testing reduces uncertainty about what a sample appears to
be. It cannot make kratom risk-free, replace medical advice or predict
an individual response.

Adults who choose to use a product should read the complete label,
keep the package and lot information, avoid combining kratom with
alcohol, sedatives, opioids or other substances without professional
guidance, avoid driving or operating machinery when impaired, and keep
products secured away from children and pets. Pregnancy and
breastfeeding require particular caution and medical guidance.

Call 911 for trouble breathing, collapse, seizure, severe confusion,
blue or gray lips, or inability to wake. In the United States, Poison
Help is available at 1-800-222-1222 for urgent exposure
guidance. Product concerns can also be reported to FDA through MedWatch
or the Safety Reporting Portal.

Frequently asked questions

1. What is kratom identity
testing?

It is a test or examination designed to determine whether a material
is the claimed ingredient—typically Mitragyna speciosa leaf or
a defined derivative form. It is separate from contaminant and potency
testing.

2.
Does a mitragynine result prove that powder is authentic kratom
leaf?

It supports the presence and measured amount of mitragynine under
that assay. By itself, it may not prove the complete species identity,
plant part, absence of added extract or purity of the powder.

3. Is DNA barcoding
the best identity test?

Not for every matrix. It can be powerful for raw leaf and some
powders, but processing can reduce usable DNA. Extracts often need
chemical and traceability evidence.

4. Can DNA testing
measure alkaloid strength?

No. DNA methods assess genetic material. Alkaloid concentration
requires a suitable quantitative chemical assay.

5.
Can an extract fail DNA testing even if it came from kratom leaf?

Yes. Extraction, heat and other processing can remove or damage DNA.
The proper result may be inconclusive rather than pass or fail.

6. What does microscopy add?

It can reveal diagnostic plant structures and unexpected tissue in
leaf fragments or powder. It becomes less useful when processing removes
those structures.

7. What is a chemical
fingerprint?

It is a defined pattern of multiple chemical features compared with
authenticated reference material using predefined acceptance rules.

8. Is one
alkaloid enough for a chemical fingerprint?

Usually not. A fingerprint generally uses multiple features. A
one-analyte assay may still be valuable for targeted quantitation.

9. Does “HPLC tested” prove
identity?

No. HPLC is an instrument technique. The method, reference, matrix,
acceptance criteria and results determine what the test supports.

10.
Does ISO/IEC 17025 accreditation prove that every lab test is
valid?

No. Review the specific laboratory location and technical scope.
Accreditation supports competence within a defined scope; it is not FDA
approval of the lab or product.

11. Why must the lot number
match?

Without a matching identifier, there may be no defensible connection
between the tested sample and the packaged product.

12. Can a generic
COA cover every future batch?

It may describe a reference or historical lot, but it does not prove
the identity or composition of later lots. Current lot-specific evidence
is stronger.

13. Are
“red,” “green” and “white” kratom laboratory identities?

They are commonly used commercial descriptions, not substitutes for
the species, plant part and processing specification.

14.
Does identity testing detect Salmonella or heavy metals?

Not unless the method separately tests those hazards. Microbiology
and elemental analyses answer different questions.

15.
Does a DNA match show that no other plant is present?

Not necessarily. Method sensitivity, primer choice, mixture
proportions and data interpretation determine whether additional species
can be detected.

16.
Does a passing identity test make a product FDA approved?

No. FDA does not approve a product simply because it passed a
laboratory test, and FDA’s current kratom marketing position remains
unchanged.

17. Is
ordinary leaf the same as concentrated 7-OH?

No. Botanical leaf contains a natural mixture of constituents, with
7-OH as a minor alkaloid. Concentrated, enhanced or manufactured 7-OH
products can have materially different composition and legal
treatment.

18. What is the best
evidence to request?

Ask for a current lot-specific report, the identity method and
acceptance criteria, authenticated reference information, sample
traceability and evidence that the method is suitable for the exact
matrix.

Sources

1. 21
   CFR §111.70 — specifications
2. 21
   CFR §111.75 — testing and examination requirements
3. 21
   CFR §111.95 — records supporting specifications
4. 21
   CFR §111.105 — quality-control responsibilities
5. FDA
   Macroanalytical Procedures Manual V-8-A, General Method for Spices,
   Herbs and Botanicals, January 2025
6. FDA Compliance
   Program 7321.008 — Dietary Supplements
7. FDA Botanical
   Drug Development Guidance for Industry
8. FDA
   and Kratom
9. Tungphatthong C. et al., Differentiation
   of Mitragyna speciosa from allied species using DNA
   barcoding–high-resolution melting, Scientific Reports 11,
   6738 (2021), DOI: 10.1038/s41598-021-86228-9.
10. Anantaworasakul P. et al., DNA Barcoding and
    Chemical Profile Using UHPLC, GC-MS and LC-MS/QTOF, Plants
    15(7), 1003 (2026), DOI: 10.3390/plants15071003.
11. Manwill P.K. et al., Kratom
    Validation: Quantitative Analysis of Indole and Oxindole Alkaloids,
    Planta Medica 88 (2022), DOI: 10.1055/a-1795-5876.
12. HHS
    7-OH threshold proceeding and September 10, 2026 comment
    deadline
13. DEA
    temporary Schedule I order for MGPI, MGM-15 and MGM-16
14. Poison Help